Author

Rachael Wen

Institution: Bristol-Myers Squibb (United States)

Observed institution: Bristol-Myers Squibb (United States)

OpenAlex ID: A5063076207

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study

2023 · Stephen M. Ansell, Paul J. Bröckelmann, et al. · Blood Advances · 96

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up

2023 · Pier Luigi Zinzani, Armando Santoro, et al. · Blood Advances · 40

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma

2023 · Armando Santoro, Alison J Moskowitz, et al. · Blood · 11

Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

2024 · Pier Luigi Zinzani, Gilles Salles, et al. · Blood Advances · 8

Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma

2025 · Nathalie A. Johnson, Pier Luigi Zinzani, et al. · Future Oncology · 1

Works count: 5

Citation count: 156

H-index: 4

I10-index: 3